Home Premarket Biotech Digest: Is Gilead Undervalued, Oncolytics' Reolysin, Novo Nordisk Reports Results
 

Keywords :   


Premarket Biotech Digest: Is Gilead Undervalued, Oncolytics' Reolysin, Novo Nordisk Reports Results

2015-07-13 18:14:55| Biotech - Topix.net

Gilead Sciences shares have once again seen a pullback in the last three weeks. Since June 24th, the stock is down nearly 7%, presenting another good opportunity to buy.

Tags: results reports novo digest

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news

»
14.11AKB48 1st
14.11kindle 10
14.11
14.11YAMAHA PORTATONE PSR-340
14.112003 112
14.11 14533.5
14.11caligari 17
14.11 amnjx 27circus
More »